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Abstract Forty-five non-small cell lung cancers (NSCLC) were 
examined for the presence of K-ras mutations in codon 12 
using RFLP (restriction fragment length polymorphism) and 
ARMS (amplification refractory mutation system) assays. 
The RFLP analysis consisted of a PCR and subsequent 
digestion of the product with BstNI. Three adenocarcinomas 
and one adenosquamous carcinoma were shown to have 
mutations at codon 12. All of these samples were also 
examined using the ARMS assay for mutations at codon 12 
and second base G to A transitions at codon 13 of the K-ras 
gene. The same four samples were confirmed to have a single 
base change in codon 12. No G to A transitions were found at 
codon 13. The four mutations were: one G to C transversion, 
one G to A transition and two G to Τ transversions. All 
mutations occurred at the second position of codon 12 as 
shown by the ARMS assay. Both of these techniques are 
rapid and reproducible for the identification of mutations in 
the K-ras gene and have potential for use in cancer diagnosis. 
Introduction 
Lung cancer is one of the most prevalent malignancies in the 
world (1). Rapid and reproducible methods for the unambiguous 
detection of molecular lesions in lung cancer at an early stage 
could have great impact on the survival and treatment of lung 
cancer patients. The ras family of oncogenes include three 
closely related genes Η-ras, N-ras and K-ras. These genes 
encode highly conserved 21-kiloDalton (kD) proteins that 
functionally resemble G-proteins and appear to be involved 
in signal transduction and cell cycle control. To date, mutations 
in these genes have been the most frequently observed genetic 
lesions in a number of human malignancies (2). In animal 
models it has been shown that ras mutations are an early event 
and have been demonstrated to precede neoplastic growth (3). 
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This also appears to be the case in some human carcinomas, 
particularly carcinomas of the colorectum. Mutated ras 
oncogenes are found in benign and malignant neoplasms of 
the colorectum at approximately the same frequency. Similar 
mutations have been found in premalignant colon tissue 
adjacent to colorectal carcinomas thereby indicating a genetic 
progression of the disease (4). In head and neck cancer, 
overexpression of the ras gene has been associated with a 
favourable prognosis and may be considered to play a role in 
the early development of the disease (5,6). Taken together, 
these findings suggest that ras mutations are an early event in 
the development of neoplasia. 
A high frequency of K-ras mutations have been detected 
in many forms of cancer including pancreatic cancers (90%), 
colorectal tumours (50%), thyroid carcinomas (30%) and 
about one third of non-small cell lung cancers (NSCLC) (2). 
The most common point mutations found in NSCLC are in 
the K-ras gene with the majority (up to 93%) occurring in 
codon 12 (7). 
In this study 45 NSCLC were analysed by two detection 
systems: a PCR, restriction fragment length polymorphism 
assay (PCR RFLP, 8) detecting mutations of codon 12 in K-ras 
and the ARMS assay (amplification refractory mutation 
system, 9) which was used to identify specific base changes 
leading to any potential non-silent codon 12 mutations and the 
G to A glycine to aspartic acid codon 13 transition. 
Materials and methods 
Sample collection. Forty-five NSCLC were obtained from 
patients undergoing lung resection for bronchial tumours 
presenting to the Cardiothoracic Centre of the Liverpool NHS 
trust. After resection the tumours were snap frozen. There were 
15 adenocarcinomas, 7 adenosquamous, 18 squamous, 3 large 
cell, 1 neuroendocrine, 1 sarcomatoid carcinoma. 
DNA extraction. High molecular weight genomic DNA was 
prepared from tumour tissue as previously described (6) 
using the Nucléon II DNA extraction kit (Scotlab) following 
the manufacturers instructions. Genomic DNA samples were 
stored at 4°C. 
PCR amplification and restriction enzyme analysis. PCR 
amplification and restriction of the product were carried out 
using the primers and protocol described by Jiang et al (8). 
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Figure 1. The principle of the ARMS assay. The 'M' (mutant) primers match the codon of interest at the final 3' with a specific hase change, as in Tahle I. If 
the 'M' primers perfectly match the DNA template then a product is formed. If the match is not perfect then no product will he made. 
Table I. Specific base changes detected by the primers for 
codon 12 and 13 of K-ras in the ARMS assay. 1 2 3 4 5 6 7 8 9 
WT 
1 st base 
2nd base 
3rd base 
Bold codons 
tests used in 
codon 
GGT 
CGT 
TGT 
AGT 
GTT 
GAT 
GCT 
GGA 
GGC 
GGG 
represent the 
this study. 
12 
giy 
arg 
cys 
ser 
val 
asp 
ala 
giy 
gly 
giy 
sequences 
codon 
GGC 
CGC 
AGC 
TGC 
GTC 
GAC 
GCC 
GGG 
GGT 
GGA 
13 
gly 
arg 
ser 
cys 
val 
asp 
ala 
gly 
giy 
gly 
amplified in the ARMS K-ras 
ARMS assay (Fig. 1 ). Terminal base 3' matched oligonucleotide 
ARMS primers were used with K-ras intron specific primers to 
amplify individual base substituted K-ras sequences (10). In 
each K-ras specific amplification two additional pairs of 
primers (unrelated to the ras gene) resulted in the generation of 
two control bands. The control products were derived from the 
alpha anti-trypsin gene sequence (360 bp product), and exon 4 
of the cystic fibrosis gene (111 bp product). See Table I for the 
specific base changes detected by the primers used for codons 
12, and 13 in K-ra.v. 
Figure 2. The PCR RFLP analysis. Lane 1, the Hindlll molecular weight 
marker; Lane 2, uncut PCR product; Lane 3, cut PCR product from a cell 
line (SW480) which is a homozygous mutant for K-ra.s; Lanes 4. 5, 6, 7. 8 
and 9 are tumour samples 56. 45. 16. 32. 47 and 5 respectively. Tumours 56 
and 16 are both wild-type, 45, 32, 47 and 5 are all mutant at codon 12 in the 
K-ras gene. 
position of K-ras codon 12. Two were G:C to T:A transversions 
resulting in an amino acid (aa) change from glycine to valine. 
One mutation was a G:C to A:T transition with a glycine to 
aspartic acid aa change while one other mutation was a G:C 
to C:G transversion with an aa change from glycine to alanine 
(Table II). Three of the mutants were adenocarcinomas and 
one was an adenosquamous carcinoma. The forty-five 
NSCLC were analysed; 20% (3/15) of the adenocarcinomas 
and 14% (1/7) of the adenosquamous carcinomas were shown 
to have a mutated K-ras gene (9% (4/45) of all NSCLC 
assayed) with no identifiable ras mutations in the squamous 
carcinomas. 
Discussion 
Results 
Four of 45 tumours analysed demonstrated K-ras mutations 
in codon 12 using RFLP, PCR followed by BstNI restriction of 
the product (see Fig. 2). The 45 specimens were also analyzed 
by ARMS analysis and the four K-ras mutations were 
confirmed (see Fig. 3). No G:C to A:T glycine to aspartic 
acid transitions were observed in codon 13 using the ARMS 
technique. All of the mutations were found to be at the second 
Mutations of the K-ra.v gene are frequently detected in a 
variety of neoplastic tissues including cancer of the pancreas, 
colon, thyroid, and lung. K-ras mutations appear to be an early 
event especially in human colorectal tumours and animal 
model systems (2,3). Current diagnostic techniques for lung 
cancer detect only 25-40% of all lung tumours which are 
considered resectable and only 20% are found to have limited 
disease at the time of resection. However patients diagnosed 
with stage I tumours have a 40-80% survival rate after 
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Figure 3. The ARMS analysis. (A), Use of the primer pair designed to test 
for codon 12 G to A transitions which results in a glycine (gly) to asparagine 
(asp) amino acid change. Lane M (on all three gels) is ΦΧ174 Haelll digest 
which has been used as a molecular weight marker. Lanes 1, 2, 3 and 4 are 
tumour samples 32, 45, 47 and 5 respectively, 47 is an asp mutant. Lane 5, 
a cell line (T3M4) which has a wild-type (WT) K-ras gene; lane 6, a known 
asp mutant cell line (SUIT2) used as positive control. Lane 7, a negative 
control run with no DNA (as is the last lane of these three gels). (B), i) 
Lanes I -6 show the results of reactions using the primer pair designed to test 
for codon 12 G to C transversions resulting in a gly to alanine (ala) amino 
acid change; ii) Lanes 7-13 show the results of reactions using the primer 
pair designed to test for codon 12 G to Τ transversions resulting in gly to 
valine (val) amino acid changes. Lanes 1, 2, 3 and 4 represent tumours 32, 
45, 47 and 5 respectively, of which 5 contains an ala mutation. Lane 5, the 
negative control cell line T3M4; lane 6, the positive control cell line 
SW1116. which is known to have an ala mutation. Lanes 7, 8, 9 and 10 
represent the results from tumours 32, 45, 47 and 5, 32 and 45 are both val 
mutants. Lane 11 is the negative control cell line T3M4 and lane 12 is the 
positive control cell line PAT12 and known val mutant. (C), Lanes 1-3 use 
the primers from (A), lanes 4-7 use primer from the first half of (B, i), lanes 8-
11 us primers from the second half of (B, ii). Lanes 3, 7 and 10 are the WT 
cell line T3M4, negative controls for each primer pair. Lanes 2, 6 and 9 are 
the mutant cell lines SUIT2 (asp mut), PATI2 (val mut) and SW1116 (ala 
mut) respectively. These are positive controls for each primer pair. Lanes 1, 
4, 5 and 8 are tumours 32, 45, 47 and 5 respectively. 
resection (11,12). Thus rapid, early and accurate identification 
of mutations in the K-ras gene would aid in the diagnosis of 
lung cancer at a potentially curable stage of the disease. In 
this study we have used two PCR based techniques to detect 
mutations in the K-ras gene which we consider will simplify 
the process of detection without loss of sensitivity. 
The PCR-RFLP assay detects any change in codon 12 of 
the K-ras gene and provides a useful primary screen as it can 
detect the majority (75-93%) of K-ras mutations reported in 
the literature on lung cancer (4,8,13-15). The technique uses 
a single base substitution in the upstream primer to create a 
BstNI restriction cleavage site (CCTGG) which is dependent 
on the two G's of codon 12 (GGT). Any change in the first 
two bases will destroy the cleavage site and the mutant would 
be detected as the product is not cleaved by BstNI. Any change 
in the third base of codon 12 of K-ras will be silent, since 
Glycine is encoded by any codon starting with GG. This 
technique is useful for screening large numbers of tumours 
Table II. Mutations detected in the K-ras gene in NSCLC. 
Tissue source 
Normal 
47 
5 
45 
32 
Base change 
-
G .A 
G-C 
G <T 
G-T 
Codon 12 
GGT 
GAT 
GCT 
GTT 
GTT 
Amino acid 
Glycine 
Asparagine 
Alanine 
Valine 
Valine 
Histology 
Adenocarcinoma 
Adenocarcinoma 
Adenocarcinoma 
Adenosquamous 
carcinoma 
The specific changes detected in the four bronchial carcinomas found to have mutations of the K-ras gene are shown. 
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quickly and accurately. We demonstrated 4 mutations in the 45 
bronchial tumours in this study using the PCR-RFLP method. 
The second technique used to identify ras in this study 
was by ARMS, a PCR based technique which uses sequence 
specific primers to amplify an area of interest. Only primers 
with an exact matching sequence at the 3' terminal position 
will amplify the DNA from the tissue. This allows the 
simultaneous detection and elucidation of the mutation from 
the sequence of the primer which successfully amplified the 
DNA of the tissue. This method confirmed the 4 mutations 
found by PCR-RFLP and also demonstrated the specific base 
changes at these sites. 
In this study no G to A transitions were found in codon 
13 in the bronchial tumours whereas 4 mutations were found 
at codon 12. Three of four of the K-ras mutations were found 
in adenocarcinomas which is consistent with the findings of 
Rodenhius and Slebos (14). However Mitsudomi et al (15) 
and Roseli et al (7) found that a third of all NSCLC examined 
were mutated at K-ras whereas our NSCLC results indicated 
only 9% contained ras mutations and 20% in adenocarcinomas. 
These techniques are accurate, rapid and reproducible 
requiring only small quantities of DNA in order to give an 
unambiguous result. The RFLP PCR technique is effective 
for screening large numbers of tumour samples quickly. The 
ARMS assay is an unambiguous confirmation of mutations 
revealing specific sequence changes occurring at codon 12 of 
K-ras. These techniques may have a potential role in the 
diagnosis and treatment of cancer. 
K-ras mutations have been successfully detected in stool, 
urine and sputum samples using labour intensive techniques 
which include phage cloning or Southern blotting of PCR 
products (12,16-18). The ARMS assay (Fox et al unpublished) 
has been shown to have at least a 1000 to 2000 fold 
sensitivity (i.e. 1 tumour cell detected in 1000 normal cells). 
Thus this technique has enormous possibilities in determining 
K-ras mutations in high risk patients with lung cancer. We are 
currently pursuing this line of research. 
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